Experimental prostate cancer therapy gets green light for one patient

NCT ID NCT06836648

AVAILABLE Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This is a special, single-patient program for someone with prostate cancer who has run out of standard options. The treatment, called X-PACT, combines a drug called methoxsalen with a phosphor device and targeted X-ray energy to attack the tumor directly. The goal is to control the cancer locally and possibly stimulate the immune system to fight it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: X-PACT (a combination of methoxsalen drug, a phosphor device, and X-ray energy)
What this could lead to: If it works, this could provide local tumor control and possibly trigger an immune response against the cancer, offering a new option for patients with few choices.
What could go wrong: This is a single-patient compassionate use, not a formal trial, so results may not apply to others. The treatment is experimental and risks are not fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital
AVAILABLE

Washington D.C., District of Columbia, 20016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.